PRNews

Frost & Sullivan Applauds CORAnet™’s Efforts to Strengthen its Brand in the Competitive Mobile Electronic Health Record Market

CORAnet™ Solutions facilitate interoperability across networks and platforms, giving patients and their families ownership and personal control of their medical records

SANTA CLARA, California, July 17, 2017 /PRNewswire/ — Based on its recent analysis of the mobile electronic health record (EHR) market, Frost & Sullivan recognizes CORAnet™ with the 2017 North America Frost & Sullivan Award for Competitive Strategy Innovation and Leadership. CORAnet™ has emerged a successful, cloud-based mobile technology solution provider, offering first responders, doctors, and individual patients 24/7 secure access to personal health records (PHRs). Its advanced software makes possible real-time access to EHR data that is exchangeable along the entire care continuum. This capability is the result of its deep understanding of sophisticated EHR healthcare information technology, health information exchanges, mobile applications, HIPAA and MU3 compliance requirements.

The greater focus on patient engagement due to the shift toward value-based care has heightened the demand for mobile PHR solutions. CORAnet™ has expertly tapped the opportunities in the market by not only delivering novel EHR solutions but also introducing an emergency medicine platform; an ambulatory platform that provides on-demand access to disparate, consolidated and organized PHRs; and a mobile telemedicine platform that offers remote access to care anywhere.

“When using the CORAnet™ solution, individual patients cannot alter any source-identified health information originating from an EHR system. This guarantees data integrity. Users may, however, add or delete diagnosed allergies, thereby safeguarding against contraindications to medications not otherwise annotated,” said Frost & Sullivan Vice President of Global Life Sciences Nitin Naik. “In addition, if the patient wishes to share EHR data using an email address, the system can generate a PDF file that is password protected.”

CORAnet™’s unique mobile solution is enabled by fully interoperable servers that facilitate access to any EHR system, projecting data in a visual, encrypted format. Outstanding features of the CORAnet™ mobile platform include:

  • A patient-facing, EHR-agnostic solution that allows EHR companies, providers, and health facilities to keep their own proprietary data
  • Aggregation of an individual’s PHR from all health system sources into medical data sets such as medical history, x-rays, laboratory results, and plan of care
  • The ability for the patient to update information on vitals, medications, allergies, and dietary supplements consumed

“CORAnet™ has emerged as an innovative technology leader that widens access to PHRs with a system comprising two demonstrative elements: the ability to integrate information from multiple EHR systems, and the ability to deliver an integrated PHR to consumer mobile devices,” said Naik. “These advantages, along with patient engagement capabilities such as appointment setting, reminders, and the option to view and share imaging files, set CORAnet™ apart as an organization that adds significant value in the new field of care collaboration.”

With more sophisticated application providers designing mobile-ready solutions, the mobile “open way” may quickly become the designated entry point for patients and doctors to access personal health data. Frost & Sullivan commends CORAnet™ for delivering a mobile exchange to support interaction, including interoperability, using multiple sensors and monitors.

“Instant access to a patient’s complete health records via CORAnet allows individuals to manage their healthcare, have peace of mind, and can minimize medical errors, hospital readmissions, and reduce costs. For providers, CORAnet is an efficient, economical tool to improve healthcare delivery and outcomes, and compliance with federal Meaningful Use (MU3) mandate for electronic health records (EHR/EMR),” said CORAnet Solutions President & CEO Cora Alisuag.

Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a competitive strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About CORAnet™

CORAnet™ Solutions, Inc. specializes in bringing mobile innovative solutions to the health care industry in the area of health management, electronic health records support, telemedicine and biometrics data predictive analytics.  CORAnet™ addresses the challenge of inefficiencies of health care by providing the interoperability, security, functionality, availability and mobility of health records. Contact us.

Contact:

P: 240 644 1555
E: info@coranetsolutions.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

Mariana Geralde is Recipient of 2017 Basic PDT Research Excellence Award

COIMBRA, Portugal, July 14, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Mariana Geralde was the recipient of the 2017 BASIC PDT RESEARCH EXCELLENCE AWARD.

Mariana Geralde was recognized for research excellence at the Sao Carlos Institute of Physics (Brazil) for her work involving the clinical application of Photodynamic Therapy (PDT) as a method to treat pulmonary infections through extracorporeal illumination. This innovative research has resulted in the significant advancement of both PDT protocols and clinical outcomes, accelerating the potential for PDT treatment of multi-drug resistant pneumonia.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

please contact: ipasecretary@internationalphotodynamic.com

Logo – http://mma.prnewswire.com/media/535806/International_Photodynamic_Association_Logo.jpg

PRNews

Venus Concept Closes $38 Million Equity Financing to Support Continued Growth Opportunities

TORONTO, July 13, 2017 /PRNewswire/ — Venus Concept Ltd., a privately-held and innovative global aesthetic technology leader, today announced the closing of a $38 million equity investment. The equity investment was led by EW Healthcare Partners along with significant participation from HealthQuest Capital and Madryn Asset Management. This financing will help support the rapid growth of Venus Concept’s industry first and only subscription-based business model, the ongoing expansion and maturation of its 27 direct global offices, and the continued development of products to serve the aesthetic marketplace.

Scott Barry, Managing Director of EW Healthcare Partners, also commented on the investment: “We are pleased to be supporting Dom and the management team of Venus Concept as they continue to successfully expand their product portfolio and services globally. We believe that their differentiated subscription model and unique products positions them well to take full advantage of tailwinds in the non-invasive aesthetic market. We are excited to participate in the growth of the company.”

In conjunction with their investments, EW Healthcare Partners and HealthQuest will each receive one seat on Venus Concept’s board of directors.

Northland Securities, Inc. acted as the sole Placement Agent for this transaction.

About Venus Concept

Venus Concept is a global medical technology company that develops, commercializes, and delivers safe, efficacious, and easy-to-use aesthetic technologies and related practice enhancement services in a unique, industry-disruptive subscription-based business model. Venus Concept’s devices have been designed in cost-effective and proprietary ways that enable the company to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets such as family practice, general practice, internal medicine, obstetrics and gynecology, and medical spas. Approximately 70 per cent of its devices are sold in non-traditional markets. The company has expanded its subscription platform and is now selling its devices in over 60 countries, including 27 with direct offices. The company now has over 400 global employees whose customer-centric approach has supported the rapid growth of the company. For more information, please visit www.venusconcept.com.

About EW Healthcare Partners

With over $3.0 billion under management, EW Healthcare Partners is one of the largest and oldest growth equity firms pursuing investments in pharmaceuticals, medical devices, healthcare services, and healthcare information technology. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of over 150 healthcare companies, ranging across sectors, stages, and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York, and London. For more information, please see www.ewhealthcare.com.

About HealthQuest Capital

HealthQuest Capital makes early growth investments in innovative commercial-stage healthcare companies that are improving both patient outcomes and healthcare economics. Investments focus on medical products, diagnostics, healthcare IT, and technology-enabled healthcare services. HealthQuest Capital is headquartered in Menlo Park, CA with west coast and east coast offices. Learn more at www.healthquestcapital.com.

About Madryn Asset Management, LP

Madryn Asset Management, LP is a leading alternative asset management firm that invests in innovative healthcare companies specializing in unique and transformative products, technologies, and services that create attractive economic opportunities. Backed by a seasoned executive management team, the firm draws upon its diverse expertise and original insights to deliver attractive returns for its limited partners while creating long-term value in support of its portfolio companies.

For further information: Melissa Kang, Phone: (888) 907-0115 ext. 139, Fax: (855) 905-0115, Email: mkang@venusconcept.com

Logo – http://mma.prnewswire.com/media/535368/VCO_StandardLogo_BLACK_Logo.jpg

PRNews

Mr. Colin Hopper Receives IPA Lifetime Achievement Award in PDT Clinical Research

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Mr. Colin Hopper was the recipient of the 2017 LIFETIME ACHIEVEMENT AWARD IN PDT CLINICAL RESEARCH.

Mr. Colin Hopper is currently the Senior Lecturer/Consultant Oral and Maxillofacial Surgeon and unit head off oral and maxillofacial surgery at University College London (UCL), Eastman Dental Institute London.  He is a Consultant Head and Neck Surgeon, University College London Hospitals and until recently Senior Research Fellow at the National Medical Laser Centre London.

Mr. Hopper spent his early career pioneering clinical protocols to confirm safety and efficacy of PDT for oncological and antimicrobial applications. Since 1991, Mr. Hopper has been working in the National Medical Centre leading a variety of research projects on the use of photodynamic therapy in the treatment of oral squamous cell carcinoma. This clinical PDT program is currently one of the world’s largest and longest running programs, documenting over 400 treatments involving the three main photosensitizers.

Mr. Hopper, long recognized for his expertise in clinical PDT, is the principal investigator on a series of ethically approved projects, including in a number of developing countries. His work has resulted in numerous publications helping to establish a clear role for PDT treatment in a variety of neoplastic conditions in the head and neck. This work has advanced rapidly by the development of interstitial treatment of tumours using image guidance systems developed with the department of imaging and medical physics.  Other related areas of research include fluorescence diagnostics (optical techniques for tissue interrogation), the use of PDT in the treatment of non-malignant conditions such as lymphangioma and the use of PDT for antimicrobial applications. Mr. Hopper dedicates considerable personal time to lecturing, mentoring and training next generations of PDT clinicians globally.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

please contact: ipasecretary@internationalphotodynamic.com

PRNews

Dr. Pilar Acedo Nunez is Recipient of 2017 IPA Early Investigator Award

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Dr. Pilar Acedo Nunez was the recipient of the 2017 IPA EARLY INVESTIGATOR AWARD.

Dr. Pilar Acedo Nunez was recognized for her exceptional research at the University College London (England) involving combination photosensitizers and photodynamic therapy which demonstrated improved efficacy and response rates in vitro and in vivo. She has been awarded several research grants, prizes and awards including a competitive two-year postdoctoral fellowship (2015) sponsored by Ramon Areces Foundation (Spain) and the Peter Samuel Royal Free Trust Fund (UK) to study at UCL under Professor Sandy MacRobert and Professor Steve Pereira.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Dr. Natalia Inada is Recipient of 2017 Award for PDT Clinical Trial Excellence

COIMBRA, Portugal, July 13, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Dr. Natalia Inada was the recipient of the 2017 AWARD FOR PDT CLINICAL TRIAL EXCELLENCE.

Dr. Natalia Inada was recognized for her leadership and fundamental role over a number of innovative Photodynamic Therapy (PDT) based trials at the Institute of Physics of Sao Carlos (Brazil). These multi-centre clinical trials involve hundreds of Latin American patients and relate to the non-surgical PDT-based treatment of skin cancer and the non-surgical PDT-based treatment of cervical intraepithelial neoplasia (CIN), for the prevention of cervical cancer. These Photodynamic treatment protocols are intended to offer minimally invasive, superior outcomes for patients in underdeveloped countries with limited public health systems. Dr. Inada was also the recent recipient of the Mercosul Science and Technology Award for the “CerCa 150 System®: a non-surgical option for cervical intraepithelial neoplasia and condyloma treatment”.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies. The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Astrocytic Gene in the Brain Determines the Language Learning Ability of Humans

– Collaboration of KIST-Ewha Womans University identified that the astrocytic gene affect changes in brain size and cognitive function.

– The genetic variation on astrocyte water channel, aquaporin-4, determines language ability.

SEOUL, South Korea, July 12, 2017 /PRNewswire/– Many studies have shown a positive correlation between brain size and cognitive function in both animals and humans, however, most studies have focused on the neuronal function in brain size and function. Although water and astrocytes* are the most common substances and components of the brain, their role in language ability are not known well. In this study, the role of aquaporin4* in brain size changes and language ability is revealed for the first time.


Activity causes volumetric plasticity via aquaporin4

*Astrocytes: Most abundant glial cells in the brain with having a star shape. They play various roles such as regulating the ion concentration and removing waste products.

*Aquaporin-4: A water channel of astrocytes in the brain, present in chromosome 18. It controls water movement in the cell membrane.

Researchers (Dr. Changjoon Lee’s group in KIST and Dr. Inkyoon Lyoo & Dr. Jieun Kim’s group in Ewha W. Univ.) found the suppression of activity-dependent astrocyte volume regulation, enriched environment-induced hippocampal volume change, and hippocampal spatial memory by inhibition of aquaporin-4 gene expression in mice. In humans, it was confirmed that the change in language-associated brain size and language ability depends on the genetic variation on aquaporin4 SNP* (rs162008), located in the 5’UTR*. In people with C base in rs162008 leading to increase of aquaporin4 expression, the semantic verbal fluency and the effect of increasing the brain size by GRE studying was higher than that in people with T base.

*SNP(Single Nucleotide Polymorphism): A common mutation occurs in one of several DNA bases in a single site on the chromosome.

*UTR(Untranslated Region): The region of mRNA, not translated into protein, refers to either of two sections, called the 5′ or 3′ UTR depending on the location.

Researchers identified a direct correlation between brain size and function. Also, they determined an essential role of astrocytes in cognitive function including language ability for the first time in the world. By controlling the aquaporin-4 gene expression, it is not only extended to other research topics such as control of brain function, but also predicts cognitive function by examining the aquaporin-4 gene mutation. It is expected that it will provide guidelines for learning by level or ability, and utilize gifted education programs and aptitude tests.

The results of the study were published in the online edition of “Molecular Psychiatry,” (IF 13.204, Top 2.42% in JCR) on Tuesday, June 27.

KIST (Korea Institute of Science and Technology)
Dr. C Justin Lee
Tel.  +82-2-958-6940
e-mail: cjl@kist.re.kr

View original content with multimedia:http://www.prnewswire.com/news-releases/astrocytic-gene-in-the-brain-determines-the-language-learning-ability-of-humans-300486790.html

PRNews

Major Beijing health investment company betting big on China’s co-working Unicorn

BEIJING, July 12, 2017 /PRNewswire/ — UrWork, Beijing — China’s largest co-working space provider UrWork announced on 5th July to add Beijing Love & Health Group (known as Beijing Aikang Group), a major Chinese conglomerate with robust investment portfolio in health and hospitality sector into its growing investor roaster, fuelling future growth in vertical development of UrWork’s service platform.


Shenzhen UrWork Alicloud space

The announcement of Beijing Love & Health Group’s strategic investment, equivalent of US$ 29.4 million, was made on July 5, seeing the two Beijing-headquartered companies to co-develop a novel co-working model, set to launch in the first half of 2018.  The announcement came two months after the announcement of the US$ 58.8 million fund injection from Star Group, China’s leading supplier of table tennis equipment and incubator for professional snooker pool players.

Dr. Wang Dong, founder and Chairman of Beijing Love & Health Group spoke highly of the investment: “Dr. Mao Daqing has demonstrated phenomenal audacity and leadership through driving UrWork from complete scratch to the Unicorn status as it is today over a short course of two years. We see this as an opportunity to extend our portfolio in real estate developments and I am confident that the strategic investment built on our shared values and complementary strengths will see UrWork going from strength to strength.”

Wang adds that UrWork’s strategic alliance with governments, the growth prospect of co-working industry, palpable commercial growth potential and strong management team are core factors that influenced the deal. He believes that UrWork sets the industrial standard and is happy to invest in a standard around which the whole industry can coalesce.  

Beijing Love & Health Group, founded in 1993, is a leading Chinese conglomerate with diversified investment portfolio in pharmaceutical and medical, securities and funds, hospitality and catering, as well as real estate sectors. With a clear health-oriented investment strategy, the company champions medical system upgrading and provides excellent post-investment support.

“This new fund injection will help further strengthen our core verticals and diversify our investor portfolio. Beijing Love & Health Group’s investment is the forerunner of a series of facility and service upgrading at UrWork and we will continue to complement our existing platform facilities and resources with targeted health hospitality real estate, and contingent resources in shared working space sector,” said Dr. Mao Daqing, founder and CEO of UrWork.

UrWork’s current investor portfolio counts the big names of the industry such as Zhen Fund, Sequoia Capital, Gopher Asset, Noah Wealth Management and Sinovation Ventures. The company is valued at US $1.3 billion after its merger with its biggest rival in China New Space in February. It counts Unicorns such as ofo, Mobike, BlueGogo, Bilibili, Today’s Headline, as well as large global enterprises such as Amazon China, JD.com as its roaster tenants.

UrWork (Beijing) Venture Investment Co., Ltd, known as UrWork, is a co-working disrupter and leader in China, providing start-ups, SMEs and corporate tenants with on-demand, short-term leasing and customised space solutions at an exceptional value. The company has last month opened its first overseas location at JTC launchpad in Singapore in tripartite partnership with Singapore International Enterprise and CapitaLand, and sets to open another 150 locations across 32 cities worldwide including Los Angeles, New York and London over the next three years, enabling community connection for 40,000 individual members and over 5000 enterprises.

While actively building economy of scale through soliciting investments, UrWork advocates consumption-upgrading in line with the central government’s national economic development scheme. Offering integrated multi-functional services and modern office facilities, UrWork platform aggregates over 1000 partner enterprise and third-party service suppliers, encompassing financial advisory, human resources, media, consultancy, international shared-medical-service platform, online sport travel commerce, intellectual property protection, intelligent hardware, start-up accelerator and interior design.

The global sharing economy in 2014 was reported to reach US$ 1.5 billion and US$ 8.1 billion by 2015. The total market capitalisation of share economy is estimated to reach US$ 335 billion, with 36% year-to-year growth rate. Assessing from the current growth trajectory, China’s sharing economy volume will crown the world within the next three to five years.

“The rising concept of co-working address the more mobile working style modern urban professionals have today, where an increasing number of people work on the go, resulting in an under-utilisation of working space. By making space more dynamic with well-crafted furniture and facilities, and supportive services, this recaptures the latent under-utilised space, which also helps drive greater cost efficiencies,” said Mao, a former real estate executive with 23 years of experiences in the commercial and residential real estate under his belt. “We are looking to diversify our portfolio and strengthen our brand asset in a bid to create a more comprehensive and inclusive ‘UrWork’ experience integrating all contexts in work and life.”

Cautionary Statement Regarding Forward-Looking Statements:

This press release contains forward-looking statements. All statements contained here that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” and similar expressions are generally intended to identify forward-looking statements. These statements are based on current expectations of UrWork company and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate or may be under the control of unrelated third parties. UrWork does not assume any obligation to update any forward-looking statements contained in this press release.

For further information please contact:

Visit http://www.urwork.cn to access more information about the facility, accelerator and mentor program from the company. 

About UrWork:

Founded in 2015 by real-estate veteran Dr. Mao Daqing, UrWork (Beijing) Venture Investment Co., Ltd is a leading co-working space provider in China offering long-term leasing, hot desk and corporate-customization solutions and professional services across a broad spectrum for small-to-medium enterprises. Backed by renowned investors such as Sequoia Capital, Zhen Fund, Noah Wealth Management, Sinovation Ventures, UrWork posts a valuation of US$ 1.3 billion after B-round as of June 2017, and has grown to cover over 78 locations in over 20 cities in China, Singapore and New York, servicing over 3000 enterprises, 40,000 members in total. UrWorks expands globally through partnership with accredited facility operators and franchisers and UrWork is the largest and most recognised co-working space brand in China. (www.urwork.cn)


UrWork at CapitaMall Minzhongleyuan, Wuhan

View original content with multimedia:http://www.prnewswire.com/news-releases/major-beijing-health-investment-company-betting-big-on-chinas-co-working-unicorn-300486296.html

PRNews

Professor Brian Wilson Receives IPA Excellence Award In Photodiagnostic Research

COIMBRA, Portugal, July 11, 2017 /PRNewswire/ — At the 16th International Photodynamic Association (IPA) World Congress in Coimbra, Professor Brian Wilson was the recipient of the 2017 EXCELLENCE AWARD IN PHOTODIAGNOSTIC RESEARCH.


Professor Brian Wilson

Dr. Brian Wilson is Professor of Medical Biophysics at Princess Margaret Cancer Centre/University Health Network, University of Toronto, Canada. He is a well-known expert and leader in the field of PDT and Photodiagnostics, internationally recognized for his pioneering research into various optic tools that can be used for minimally-invasive cancer treatment, and early diagnosis and optically-guided cancer therapeutics. He holds several awards in biomedical optics (Mark Award, NIH Translational Research Award, Michael S. Feld Award and Britton Chance Award) and in cancer research (Robert L. Noble Prize).

In 1981, Dr. Wilson initiated translational research and collaborative clinical trials of photodynamic therapy for brain, prostate and gastrointestinal cancers. Dr. Wilson leads a world-renowned R&D program in optics-based biomedical applications, with a primary translational/clinical focus. He has driven the development of fluorescence and other endoscopic imaging techniques – particularly in Barrett’s esophagus and colon cancer – and more recently has developed optical imaging to guide surgery that is being evaluated in clinical trials for head and neck, prostate and brain cancers. In the last few years, his research has expanded to include development of photonic nanoparticles in cancer treatment, diagnosis and research. Dr. Wilson has published over 350 peer-reviewed papers in basic, translational and clinical research. With several international Visiting Appointments (Harvard, USA; Saõ Paulo, Brazil; Fujian, China; Western Australia), Dr. Wilson is involved in many national and international collaborations. Dr. Wilson has trained more than 50 graduate students, post-doctoral and clinical fellows, many of whom remain in biomedical optics, cancer research and practice worldwide. He also has worked with many companies nationally and internationally in translating optical technologies into clinical practice.

The Coimbra World Congress was the 16th conference held by the International Photodynamic Association, marking 32 years of this global meeting. The IPA World Congresses, held every two years, are the leading PDT meetings bringing together members of the global photodynamic community in order to advance scientific and clinical research relating to photodiagnosis and photodynamic therapies.  The next IPA World Congress is to be hosted in Boston, USA and will be led by Dr. Tayyaba Hasan, Professor of Dermatology at the Wellman Center for Photomedicine, Harvard Medical School (HMS) and a Professor of Health Sciences and Technology (Harvard-MIT).  

About Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) is a combination therapy involving light activated photosensitizers to diagnose and treat various types of cancers and pre-cancers, macular degeneration and multidrug resistant biofilm infections involving bacteria, viruses and fungi.

For more information, please contact: ipasecretary@internationalphotodynamic.com

PRNews

Burjeel Hospital Wins ‘2017 UAE Emerging Medical Tourism Service Provider of the Year – Hospital Category’ Award at the 2017 Frost & Sullivan Middle East Best Practices Awards

DUBAI, United Arab Emirates, July 6, 2017 /PRNewswire/ — Burjeel Hospital (A unit of VPS Healthcare) was named ‘2017 UAE Emerging Medical Tourism Service Provider of the Year- Hospital Category‘ at the 2017 Frost & Sullivan Middle East Best Practices Awards Banquet held on 24th May at Atlantis, The Palm in Dubai.


Dr. Raja Gujju, Chief Operating Officer & Dr.Nabil Debouni, Medical Director, Burjeel Hospital receives the 2017 UAE Emerging Medical Tourism Service Provider of the Year – Hospital Category Award from Mr. Jamal Ramadhan Bin Marghoob, Director Marketing & Corporate Communications, from Dubai Airport Freezone in presence of Mr. Sandeep Sinha, Vice President, Transformational Health Practice, Frost & Sullivan

Burjeel Hospital Abu Dhabi is an emerging medical tourism service provider in the UAE. It caters to the growing medical needs of the UAE and GCC by offering high quality care in all medical specialties. The top five specialties in Burjeel Hospital Abu Dhabi, for international patients, include obstetrics, gynecology, orthopedics, neonatology, general surgery and gastroenterology. It offers special packages for cesarean section, bariatric surgery and hip replacement. Established in 2012, the hospital is currently expanding its operational beds to accommodate the growing needs of the local and international populace.

“We are truly honored to be recognized in this category by Frost & Sullivan this year. The award underlines our commitment as an organization to provide the best healthcare in the region and significantly contribute in enhancing the area of medical tourism in the UAE,” said Dr. Raja Gujju, Chief Operating Officer, Burjeel Hospital – Abu Dhabi.

Congratulating Burjeel Hospital Abu Dhabi on the award, Mr. Sandeep Sinha, Vice President, Transformational Health Practice, Frost & Sullivan said, “2016 has been a very successful year for Burjeel Hospital Abu Dhabi. The company’s international patient department contributed 34 percent to the total revenue of the hospital with an inflow of more than 8,000 international patients. The hospital not only provides world-class tertiary healthcare in the region, it also enhances the patient’s experience by managing their logistic needs, including visa and travel arrangements, hotel stays, dietary services, religious needs and airport transfer, thus delivering a stress-free experience. Its growth, unique services, marketing initiatives, technical advancements and the compassionate patient-centric approach are some of the key factors which have contributed to its leading position in the region.”

Frost & Sullivan Awards recognize companies across regional and global markets for outstanding achievement and performance in a range of regional and global markets for superior leadership, technological innovation, customer service, strategic product development among others.

Frost & Sullivan’s robust research methodology represents the analytical rigor of our research process. It offers a 360-degree-view of industry challenges, trends, and issues by integrating all 7 research methodologies. Too often, companies make important growth decisions based on a narrow understanding of their environment, leading to errors of both omission and commission. Successful growth strategies are founded on a thorough understanding of market, technical, economic, financial, customer, best practices, and demographic analyses. The integration of these research disciplines into the 360-degree research methodology provides an evaluation platform for benchmarking industry players and for identifying those performing at best-in-class levels.

About Burjeel Hospital

Burjeel Hospital is Abu Dhabi’s premier private healthcare facility providing world-class, specialized and superior healthcare complemented by a warm and personalized human touch to the growing population of the emirate of Abu Dhabi.

A unit of the VPS Healthcare, Burjeel Hospital opened for patients in April 2012 as a Tertiary hospital under the auspices of the Health Authority for Abu Dhabi.  At the core of the organization is a team of exceptionally skilled and highly experienced health professionals, collaborating as multidisciplinary teams with guests and their families as the main focus, to provide the best healthcare experience. 

Burjeel Hospital received the prestigious Joint Commission International (JCI) accreditation in June 2013 – 15 months after starting operations and the hospital was granted JCI Re-accreditation in Aug 2016. Currently, the hospital is affiliated with some of the world’s best healthcare institutions for its centers of excellence and is now becoming a renowned center of referral for Cardiovascular, Orthopedics, Ophthalmology, Pediatrics, Obstetrics and Gynecology, Reproductive Medicine, Oncology and many more specialties handling complex laparoscopic and minimally invasive surgeries. The hospital has full-fledged pharmacy, laboratory, and radiology units to serve guests at any time of the day. Burjeel also houses a restaurant and a coffee shop, serving the finest and healthiest cuisines from across the world. Combining all-round specialization and expertise with most advanced technology, Burjeel offers the best in diagnostic, curative, as well as preventive aspects of healthcare.

For more details, visit the website at www.burjeel.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

For Frost & Sullivan

Anita Chandhoke
Corporate Communications
C: +91 99161 33311
P: +91.80.6702 8020
E: achandhoke@frost.com
http://www.frost.com

For Burjeel Hospital

Joanne Rico
Marketing and Business Development Department
C: +971 8841 669
P: +971 2 508 5656
E: joanne.rico@burjeel.com 
www.burjeel.com

Photo – http://mma.prnewswire.com/media/530941/Burjeel_Hospital_Frost_Sullivan_Award.jpg

Exit mobile version